|Bid||68.61 x 1200|
|Ask||68.63 x 1300|
|Day's Range||68.40 - 69.33|
|52 Week Range||66.62 - 110.20|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||18.01|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / U.S. stocks closed in the red on Friday as U.S. jobs report fell short of expectations and uncertainty over the U.S. -China trade talk spur markets lower. ...
82% overall response rate observed in heavily pre-treated patients
Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo
The data were presented by Nina Shah, M.D., University of California, San Francisco, as an oral presentation at the 60th Annual Meeting of the American Society of Hematology (ASH). bb21217 is an investigational anti-BCMA CAR T cell therapy that uses the bb2121 chimeric antigen receptor (CAR) molecule with a manufacturing process designed to improve CAR T cell functional persistence. “Anti-BCMA CAR T therapy with bb2121 has shown clinical responses in a substantial proportion of patients with relapsed/refractory multiple myeloma.
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to pl
Eighty one percent overall response rate and 43% complete response rate observed in heavily pre-treated patients
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo
Celgene Corporation (CELG) and bluebird bio, Inc. (BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma. “We continue to be excited about bb2121 as a potential first-in-class BCMA-targeted therapy for patients with multiple myeloma,” said Alise Reicin, M.D., President, Global Clinical Development for Celgene. “We would like to thank everyone who enabled this achievement, especially the patients and caregivers, and we congratulate the physicians and others involved in the KarMMa study, including our dedicated partners at bluebird bio.
NEW YORK, NY / ACCESSWIRE / November 20, 2018 / Wall Street posted sharp losses on Monday as drop in information technology shares and pressured broader market lower. The Dow Jones Industrial Average was ...
NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, announced it is joining forces with Celgene (CELG) to launch Addressing Unmet Needs in MS: An Innovation Challenge, to seek new solutions aimed at addressing the daily challenges associated with multiple sclerosis (MS). The Innovation Challenge will take place in May 2019 and will be open to patient entrepreneurs—those who have been affected by MS as either a patient, loved one or support partner—whose companies are helping develop solutions to address an unmet need in multiple sclerosis. The goal of the innovation challenge is to shed light on the endeavors and ideas of patient entrepreneurs while raising awareness about this chronic condition.
Celgene Corporation (CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Presentations will cover a wide range of blood diseases including multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes and be
NEW YORK, Oct. 31, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / October 25, 2018 / U.S. stocks plunged on Wednesday as a sharp selloff in technology shares was triggered by losses from the FANG stocks (Facebook, Amazon, Netflix and Google ...
Celgene Launches Campaign to Encourage Others to Look Beyond the Surface of the Condition
Celgene Corporation today announced results from an open-label phase II/III National Clinical Trials Network study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute , part of the National Institutes of Health.
Dr. Alise Reicin will lead mid- to late-stage drug development across Celgene’s portfolio
IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy combination in first-line metastatic triple negative breas
A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. The survey, conducted by the Multiple Sclerosis Association of America (MSAA) and sponsored by Celgene, included more than 1,300 people with multiple sclerosis or someone responding on their behalf.
Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial
Celgene Corporation (CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo. In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole body itch numeric rating scale (NRS) [defined as at least a 4-point reduction from baseline] at week 16 with OTEZLA versus placebo. The safety profile was generally consistent with the known safety profile of OTEZLA, and no new safety signals were identified in the trial.
Celgene Corporation (CELG) will host a conference call and live audio webcast on Thursday, October 25, 2018 at 9 a.m. ET to discuss third quarter 2018 financial and operational results. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.